Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 2Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 6Gastrointestinal 4Genitourinary 3Breast 3Sarcoma 2Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Leiomyosarcoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 9Radiotherapy 8Temozolomide 6Magnetic Resonance Spectroscopy 6Filgrastim 6Doxorubicin 6pazopanib 5Gemcitabine 5pembrolizumab 4Vincristine 4Radiation 4Etoposide 4Docetaxel 4Carboplatin 4Biopsy 4Trabectedin 3Taxes 3Specimen Handling 3Paclitaxel 3Nivolumab 3Irinotecan 3Drug Therapy 3olaparib 2niraparib 2liposomal doxorubicin 2fludarabine phosphate 2fludarabine 2brigimadlin 2Trastuzumab 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × niraparib × Sarcoma × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡